WeedMD has 165% upside, Mackie Research says

Amid a flurry of activity, Mackie Research Capital analyst Greg McLeish has resumed coverage of WeedMD (TSX:WMD) with the same bullish take.

In a research update to clients today, McLeish maintained his “Buy” rating and one-year price target of $4.00 on WeedMD, implying a return of 164.9 per cent at the time of publication.

McLeish notes that WeedMD on July 10 terminated its agreement with Hiku Brands, which was instead acquired by Canopy Growth Corp. But the exercise was not one of complete futility, the analyst points out, because WMD received a $10-million termination fee in connection with the arrangement.

“The company currently has $50 mm in net cash and it is fully funded for 50,000 kg of cannabis production capacity at existing licensed facilities,” the analyst notes. “This strong cash position will also allow management to pursue strategic acquisitions and address potential working capital requirements.”

McLeish thinks WeedMD will generate EBITDA of negative $6.5-million on revenue of $19.1-million in fiscal 2018. He expects those numbers will improve to EBITDA of $16.6-million on a topline of $73.6-million the following year.

About Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Primary Sidebar

Win This Book!

We're giving away a copy of the international best seller "The Snowball: Warren Buffett and the Business of Life" by Alice Schroeder. All you have to do is sign up for Cantech Letter Alerts below: